At its 2026 annual meeting held on June 17, 2026, Acrivon Therapeutics, Inc. stockholders approved the Amended and Restated 2022 Equity Incentive Plan. This plan increases the aggregate share reserve to 8,606,723 shares, including a 3,000,000 share increase. The plan also includes an automatic annual share reserve increase of 5% of fully diluted shares through 2032. Additionally, Michael Tomsicek and Charles Baum were elected as Class I directors, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm. Acrivon Therapeutics, Inc. is a biotechnology company focused on developing therapeutics.